----

*Exhibit 99.1*
|  |  Progenics Pharmaceuticals, Inc.777 Old Saw Mill River RoadTarrytown, New York 10591914-789-2800www.progenics.com  |
|--|------------------------------------------------------------------------------------------------------------------------------|
| Contact:  | Melissa DownsInvestor Relations(914) 789-2801mdowns@progenics.com |
|----------------|-------------------------------------------------------------------|
|                     |   | Net Relistor Sales |
|--------------------------|--------|--------------------|
|                     |   | Three Months Ended |   |   | Six Months Ended |
|                     |   | June 30,           |   |   | March 31, |   |   | June 30, |
|                     |   | 2014               |   |   | 2013 |   |   | 2014 |   |   | 2014 |   |   | 2013 |
| U.S.                     |   | $                  | 8.2 |   |   | $ | 6.7 |   |   | $ | 3.6 |   |   | $ | 11.8 |   |   | $ | 13.4 |
| Ex-U.S.                  |   |               | 0.9 |   |   |   | 1.2 |   |   |   | 1.2 |   |   |   | 2.1 |   |   |   | 2.2 |
|    Global |   | $                  | 9.1 |   |   | $ | 7.9 |   |   | $ | 4.8 |   |   | $ | 13.9 |   |   | $ | 15.6 |

----

| ● | The U.S. Food and Drug Administration said on July 10 that the sNDA expanding Relistor's indication to include chronic non-cancer pain patients with OIC can be approved on the data previously submitted in that filing. The decision follows Salix's appeal of the agency's Complete Response Letter on the filing two years ago and an Advisory Committee convened by the FDA last month. Salix submitted to the agency on July 25 information required for final approval, and we expect a two-month review. |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |   |
| ● | Salix has said it intends to meet with the FDA as soon as possible to discuss a path forward for oral Relistor for the treatment of OIC in patients with chronic, non-cancer pain.                                                                                                                                                                                                                                                                                                                                    |
|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  |
| ● | Results from two trials of the Company's small molecule PSMA imaging agent for prostate cancer, 1404, are scheduled to be presented at a featured oral session during the annual meeting of the European Association of Nuclear Medicine (EANM) in Gothenburg, Sweden on in October.                                                                                                                                                                                                                                       |
|    | ⃝                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | The phase 2 complete study results involving 104 patients are to be presented by Dr. Gabriella Dabasi of Semmelweis University. |
|    | ⃝                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Dr. Shankar Vallabhajosula of Cornell University's Medical College is to present phase 1 pilot study results on nine patients. |

----

| PROGENICS PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except net loss per share) |   |
|--------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                     |   | For the Three Months EndedJune 30, |   |   | For the Six Months EndedJune 30, |   |
|                                                                                                                     |   | 2014 |   |   | 2013 |   |   | 2014 |   |   | 2013 |   |
| Revenues:                                                                                                                |   |  |   |   |  |   |   |  |   |   |  |   |
|   Royalty income                                                                                               |   | $ | 1,367 |   |   | $ | 1,176 |   |   | $ | 2,102 |   |   | $ | 2,333 |   |
|   Collaboration revenue                                                                                        |   |   | 72 |   |   |   | 514 |   |   |   | 1,121 |   |   |   | 1,367 |   |
|   Research grants                                                                                              |   |   | - |   |   |   | 77 |   |   |   | - |   |   |   | 275 |   |
|   Other revenues                                                                                               |   |   | 38 |   |   |   | 34 |   |   |   | 69 |   |   |   | 52 |   |
|      Total revenues                                                                             |   |   | 1,477 |   |   |   | 1,801 |   |   |   | 3,292 |   |   |   | 4,027 |   |
|                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Expenses:                                                                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Research and development                                                                               |   |   | 7,848 |   |   |   | 9,585 |   |   |   | 14,767 |   |   |   | 18,300 |   |
|    License fees – research and development                                                          |   |   | 180 |   |   |   | 153 |   |   |   | 270 |   |   |   | 223 |   |
|    Royalty expense                                                                                        |   |   | 147 |   |   |   | 119 |   |   |   | 229 |   |   |   | 235 |   |
|    General and administrative                                                                             |   |   | 4,256 |   |   |   | 3,899 |   |   |   | 8,161 |   |   |   | 8,219 |   |
|    Depreciation and amortization                                                                          |   |   | 133 |   |   |   | 318 |   |   |   | 277 |   |   |   | 595 |   |
|       Total expenses                                                                       |   |   | 12,564 |   |   |   | 14,074 |   |   |   | 23,704 |   |   |   | 27,572 |   |
|                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Operating loss                                                                                                           |   |   | (11,087 | ) |   |   | (12,273 | ) |   |   | (20,412 | ) |   |   | (23,545 | ) |
|                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other income:                                                                                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|    Interest income                                                                                        |   |   | 13 |   |   |   | 10 |   |   |   | 25 |   |   |   | 24 |   |
|       Total other income                                                                   |   |   | 13 |   |   |   | 10 |   |   |   | 25 |   |   |   | 24 |   |
|                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss before income tax benefit                                                                                       |   |   | (11,074 | ) |   |   | (12,263 | ) |   |   | (20,387 | ) |   |   | (23,521 | ) |
|                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Income tax benefit                                                                                                       |   |   | 1 |   |   |   | - |   |   |   | 1 |   |   |   | - |   |
|                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                                                                                 |   | $ | (11,073 | ) |   | $ | (12,263 | ) |   | $ | (20,386 | ) |   | $ | (23,521 | ) |
|                                                                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss per share; basic and diluted                                                                                    |   | $ | (0.17 | ) |   | $ | (0.24 | ) |   | $ | (0.31 | ) |   | $ | (0.46 | ) |
| Weighted average shares outstanding; basic and diluted                                                                   |   |   | 63,743 |   |   |   | 51,481 |   |   |   | 66,775 |   |   |   | 50,802 |   |
| CONDENSED CONSOLIDATED BALANCE SHEETS(unaudited)(in thousands) |   |
|----------------------------------------------------------------|--------|
|                                                           |   | June 30,2014 |   |   | December 31,2013 |   |
|                                                           |   |  |   |   |  |   |
| Cash and cash equivalents                                      |   | $ | 85,347 |   |   | $ | 65,860 |   |
| Accounts receivable, net                                       |   |   | 1,468 |   |   |   | 2,879 |   |
| Auction rate securities                                        |   |   | 2,208 |   |   |   | 2,208 |   |
| Fixed assets, net                                              |   |   | 2,203 |   |   |   | 2,413 |   |
| Intangible assets, net and goodwill                            |   |   | 39,079 |   |   |   | 39,081 |   |
| Other assets                                                   |   |   | 2,100 |   |   |   | 2,100 |   |
|    Total assets                                 |   | $ | 132,405 |   |   | $ | 114,541 |   |
|                                                           |   |   |   |   |   |   |   |   |
| Current liabilities                                            |   | $ | 4,352 |   |   | $ | 6,627 |   |
| Contingent consideration liability                             |   |   | 16,600 |   |   |   | 15,700 |   |
| Deferred tax and other liabilities                             |   |   | 13,232 |   |   |   | 13,235 |   |
|     Total liabilities                      |   |   | 34,184 |   |   |   | 35,562 |   |
|     Stockholders' equity                   |   |   | 98,221 |   |   |   | 78,979 |   |
| Total liabilities and stockholders' equity                     |   | $ | 132,405 |   |   | $ | 114,541 |   |

----

----